Sierra Oncology Inc (NASDAQ:SRRA)
Stock Price:
$54.99
+0.02
(0.04%)
Updated
Jun 30, 2022 08:00 PM GMT+0000
| Market Cap | 1.34B |
|---|---|
| Revenue | 0 |
| Gross Profit | 0 |
| Shares Out | 24.42M |
| EPS (ttm) | |
| PE Ratio | 0.0000 |
| Forward PE | 0.0000 |
| Dividend Rate (ttm) | 0.0000 |
| Dividend Yield | 0.0000 |
| Trading Day | Jun 30 |
|---|---|
| Last Price | $54.99 |
| Previous Close | $54.97 |
| Change ($) | 0.02 |
| Change (%) | 0.04% |
| Day's Open | 54.97 |
| Day's Range | 54.99 - 54.99 |
| Day's Volume | 0 |
| 52 Week Range | 14.91 - 55.19 |
About Sierra Oncology Inc
Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology.
Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
News
Quick info
Country
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Employees
69
CEO
Stephen Dilly
Address
2150 ? 885 West Georgia Street
Vancouver
British Columbia
V6C 3E8
Vancouver
British Columbia
V6C 3E8
Phone
16045586536
Website
www.sierraoncology.com
Ticker Symbol
SRRA
Exchange
NASDAQ Stock Exchange
Reporting Currency
USD
Sierra Oncology Inc income statements (2020) (USD)
| June 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|
| Total Revenue | N.A | N.A | N.A | N.A |
| Cost of Revenue | 58K | 58K | 55K | 55K |
| Gross Profit | -58K | -58K | -55K | -55K |
| Research & Development | 10.19M | 10.19M | 11.59M | 11.59M |
| Selling General & Admin | 6.20M | 6.20M | 4.49M | 4.49M |
| Operating Expense | 16.45M | 16.45M | 16.14M | 16.14M |
| Operating Income | -16.45M | -16.45M | -16.14M | -16.14M |
| Other Income Expense Net | -24K | -24K | -15.7M | -15.7M |
| EBIT | -16.45M | -16.45M | -16.14M | -16.14M |
| Interest Income | N.A | N.A | N.A | N.A |
| Pretax Income | -16.47M | -16.47M | -31.83M | -31.83M |
| Income Tax | -11K | -11K | 78K | 78K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -16.46M | -16.46M | -31.91M | -31.91M |
| Net Income Basic | -16.46M | -16.46M | -31.91M | -31.91M |
Sierra Oncology Inc income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | N.A | N.A | N.A | N.A |
| Cost of Revenue | N.A | 62K | 64K | 62K |
| Gross Profit | N.A | -62K | -64K | -62K |
| Research & Development | 21.27M | 10.11M | 11.73M | 10.14M |
| Selling General & Admin | 3.75M | 3.09M | 3.42M | 3.30M |
| Operating Expense | 25.02M | 13.26M | 15.21M | 13.50M |
| Operating Income | -25.02M | -13.26M | -15.21M | -13.5M |
| Other Income Expense Net | -22.4M | 288K | 348K | 325K |
| EBIT | -25.02M | -13.26M | -15.21M | -13.5M |
| Interest Income | 500K | 100K | 100K | 100K |
| Pretax Income | -47.42M | -12.98M | -14.86M | -13.18M |
| Income Tax | 39K | -73K | 19K | -145K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -47.46M | -12.9M | -14.88M | -13.03M |
| Net Income Basic | -47.46M | -12.9M | -14.88M | -13.03M |
Sierra Oncology Inc income statements (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Total Revenue | N.A | N.A | N.A | N.A |
| Cost of Revenue | 26K | 26K | 30K | 29K |
| Gross Profit | -26K | -26K | -30K | -29K |
| Research & Development | 10.96M | 12.91M | 8.79M | 8.33M |
| Selling General & Admin | 3.58M | 3.11M | 4.15M | 3.39M |
| Operating Expense | 14.56M | 16.05M | 12.96M | 11.75M |
| Operating Income | -14.56M | -16.05M | -12.96M | -11.75M |
| Other Income Expense Net | 358K | 479K | 582K | 272K |
| EBIT | -14.56M | -16.05M | -12.96M | -11.75M |
| Interest Income | N.A | N.A | N.A | N.A |
| Pretax Income | -14.2M | -15.57M | -12.38M | -11.48M |
| Income Tax | 81K | -5K | -421K | 43K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -14.28M | -15.57M | -11.96M | -11.53M |
| Net Income Basic | -14.28M | -15.57M | -11.96M | -11.53M |
Sierra Oncology Inc income statements (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Total Revenue | N.A | N.A | N.A |
| Cost of Revenue | 30K | 72K | 103K |
| Gross Profit | -30K | -72K | -103K |
| Research & Development | 7.59M | 7.37M | 7.17M |
| Selling General & Admin | 3.23M | 2.71M | 3.18M |
| Operating Expense | 10.85M | 10.15M | 10.45M |
| Operating Income | -10.85M | -10.15M | -10.45M |
| Other Income Expense Net | 297K | 187K | 156K |
| EBIT | -10.85M | -10.15M | -10.45M |
| Interest Income | N.A | N.A | N.A |
| Pretax Income | -10.55M | -9.96M | -10.29M |
| Income Tax | 48K | 37K | 37K |
| Minority Interest | 0 | 0 | 0 |
| Net Income | -10.6M | -10M | -10.33M |
| Net Income Basic | -10.6M | -10M | -10.33M |
Sierra Oncology Inc balance sheet (2020) (USD)
| June 2020 | March 2020 | March 2020 | |
|---|---|---|---|
| Current Cash | 123.23M | 133.53M | 133.53M |
| Receivables | N.A | N.A | N.A |
| Inventory | N.A | N.A | N.A |
| Current Assets | 124.63M | 135.47M | 135.47M |
| Other Current Assets | 1.16M | 1.78M | 1.78M |
| Short Term Investments | N.A | N.A | N.A |
| Long Term Investments | 300K | 300K | 300K |
| Property/Plant Equipment | 601K | 659K | 659K |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A |
| Tangible Assets (Net) | 116.65M | 129.50M | 129.50M |
| Other Assets | 367K | 362K | 362K |
| Total Assets | 125.89M | 136.79M | 136.79M |
| Accounts Payable | 1.98M | 1.36M | 1.36M |
| Other Current Liabilities | 6.81M | 5.47M | 5.47M |
| Total Current Liabilities | 8.98M | 7M | 7M |
| Total Liabilities | 9.24M | 7.30M | 7.30M |
| Long Term Debt | 261K | 298K | 298K |
| Current Long Term Debt | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 |
| Common Stock | 10.40M | 10.40M | 10.40M |
| Treasury Stock | N.A | N.A | N.A |
| Retained Earnings | -814.06M | -797.6M | -797.6M |
| Capital Surplus | 0.93B | 0.93B | 0.93B |
| Shareholder Equity | 116.65M | 129.50M | 129.50M |
| Other Liabilities | N.A | N.A | N.A |
Sierra Oncology Inc balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 147.53M | 67.69M | 78.83M | 90.91M |
| Receivables | N.A | N.A | N.A | N.A |
| Inventory | N.A | N.A | N.A | N.A |
| Current Assets | 149.90M | 70.81M | 82.59M | 94.61M |
| Other Current Assets | 2.17M | 2.98M | 2.19M | 2.07M |
| Short Term Investments | N.A | N.A | N.A | N.A |
| Long Term Investments | 300K | 300K | 300K | 300K |
| Property/Plant Equipment | 702K | 767K | 805K | 866K |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A | N.A |
| Tangible Assets (Net) | 86.35M | 58.85M | 70.47M | 83.59M |
| Other Assets | 429K | 438K | 478K | 322K |
| Total Assets | 151.33M | 72.32M | 84.18M | 96.10M |
| Accounts Payable | 1.02M | 1.30M | N.A | N.A |
| Other Current Liabilities | 63.40M | 6.56M | 8.09M | 6.90M |
| Total Current Liabilities | 64.61M | 9.21M | 8.94M | 7.24M |
| Total Liabilities | 64.98M | 13.47M | 13.70M | 12.50M |
| Long Term Debt | 374K | 4.26M | 4.77M | 5.27M |
| Current Long Term Debt | N.A | 1.17M | 668K | 168K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 1.87M | 74.69M | 74.69M | 74.69M |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | -765.69M | -718.23M | -705.32M | -690.44M |
| Capital Surplus | 851.96M | 777M | 775.72M | 773.96M |
| Shareholder Equity | 86.35M | 58.85M | 70.47M | 83.59M |
| Other Liabilities | N.A | N.A | N.A | N.A |
Sierra Oncology Inc balance sheet (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Current Cash | 106.05M | 116.13M | N.A | 133.83M |
| Receivables | N.A | N.A | N.A | N.A |
| Inventory | N.A | N.A | N.A | N.A |
| Current Assets | 108.75M | 119.33M | 127.85M | 135.99M |
| Other Current Assets | 1.79M | 2.50M | 1.70M | 1.83M |
| Short Term Investments | N.A | N.A | N.A | N.A |
| Long Term Investments | 300K | 300K | 300K | 175K |
| Property/Plant Equipment | 168K | 125K | 121K | 144K |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A | N.A |
| Tangible Assets (Net) | 94.48M | 107.07M | 120.65M | 130.80M |
| Other Assets | 249K | 296K | 278K | 128K |
| Total Assets | 109.47M | 120.05M | 128.55M | 136.44M |
| Accounts Payable | N.A | N.A | N.A | N.A |
| Other Current Liabilities | 10.10M | 8.13M | 7.90M | 5.64M |
| Total Current Liabilities | 10.10M | 8.13M | 7.90M | 5.64M |
| Total Liabilities | 14.99M | 12.99M | 7.90M | 5.64M |
| Long Term Debt | 4.89M | 4.86M | N.A | N.A |
| Current Long Term Debt | N.A | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 74.37M | 74.36M | 74.33M | 74.31M |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | -677.41M | -663.13M | -647.56M | -635.6M |
| Capital Surplus | 771.82M | 770.12M | 768.14M | 766.33M |
| Shareholder Equity | 94.48M | 107.07M | 120.65M | 130.80M |
| Other Liabilities | N.A | N.A | N.A | N.A |
Sierra Oncology Inc balance sheet (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Current Cash | 100.35M | 107.82M | 116.70M |
| Receivables | N.A | N.A | N.A |
| Inventory | N.A | N.A | N.A |
| Current Assets | 101.73M | 109.57M | 117.27M |
| Other Current Assets | 1.27M | 1.65M | 475K |
| Short Term Investments | N.A | N.A | N.A |
| Long Term Investments | 200K | 200K | 200K |
| Property/Plant Equipment | 154K | 183K | 256K |
| Good Will | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A |
| Tangible Assets (Net) | 94.73M | 103.78M | 112.31M |
| Other Assets | 119K | 113K | 112K |
| Total Assets | 102.20M | 110.07M | 117.83M |
| Accounts Payable | N.A | N.A | N.A |
| Other Current Liabilities | 7.47M | 6.29M | 5.52M |
| Total Current Liabilities | 7.47M | 6.29M | 5.52M |
| Total Liabilities | 7.47M | 6.29M | 5.52M |
| Long Term Debt | N.A | N.A | N.A |
| Current Long Term Debt | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 |
| Common Stock | 52.40M | 52.27M | 52.27M |
| Treasury Stock | N.A | N.A | N.A |
| Retained Earnings | -624.08M | -613.48M | -603.48M |
| Capital Surplus | 718.75M | 717.20M | 715.74M |
| Shareholder Equity | 94.73M | 103.78M | 112.31M |
| Other Liabilities | N.A | N.A | N.A |
Sierra Oncology Inc cash flow (2020) (USD)
| June 2020 | March 2020 | |
|---|---|---|
| Net Income | -16.46M | -31.91M |
| Depreciation | 58K | 55K |
| Changes in Receivables | N.A | N.A |
| Changes in Inventories | N.A | N.A |
| Cash Change | -10.3M | -13.99M |
| Cash Flow | -10.28M | -13.95M |
| Capital Expenditures | -12K | N.A |
| Investments | N.A | N.A |
| Investing Activity (other) | N.A | N.A |
| Total Investing Cash Flows | -12K | N.A |
| Dividends Paid | N.A | N.A |
| Net Borrowings | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A |
| Cash Flow Financing | N.A | N.A |
| Exchange Rate Effect | -12K | -46K |
Sierra Oncology Inc cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | -47.46M | -12.9M | -14.88M | -13.03M |
| Depreciation | -105K | 62K | 64K | 62K |
| Changes in Receivables | N.A | N.A | N.A | N.A |
| Changes in Inventories | N.A | N.A | N.A | N.A |
| Cash Change | 79.83M | -11.14M | -12.08M | -15.14M |
| Cash Flow | -12.46M | -11.11M | -12.06M | -15.57M |
| Capital Expenditures | -6K | -14K | -5K | -14K |
| Investments | N.A | N.A | N.A | N.A |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -6K | -14K | -5K | -14K |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | -5.44M | N.A | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | N.A | N.A |
| Cash Flow Financing | 92.29M | N.A | N.A | 445K |
| Exchange Rate Effect | 2K | -17K | -16K | -3K |
Sierra Oncology Inc cash flow (2018) (USD)
| December 2018 | September 2018 | June 2018 | March 2018 | |
|---|---|---|---|---|
| Net Income | -14.28M | -15.57M | -11.96M | -11.53M |
| Depreciation | 26K | 26K | 30K | 29K |
| Changes in Receivables | N.A | N.A | N.A | N.A |
| Changes in Inventories | N.A | N.A | N.A | N.A |
| Cash Change | -10.08M | -9.3M | -8.28M | 33.47M |
| Cash Flow | -9.97M | -14.27M | -8.27M | -12.61M |
| Capital Expenditures | -59K | -29K | -30K | N.A |
| Investments | N.A | N.A | N.A | N.A |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | -59K | -29K | -30K | N.A |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | N.A | 4.96M | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | N.A | N.A |
| Cash Flow Financing | 2K | 5M | 32K | 46.10M |
| Exchange Rate Effect | -52K | -3K | -13K | -20K |
Sierra Oncology Inc cash flow (2017) (USD)
| December 2017 | September 2017 | June 2017 | |
|---|---|---|---|
| Net Income | -10.6M | -10M | -10.33M |
| Depreciation | 30K | 72K | 103K |
| Changes in Receivables | N.A | N.A | N.A |
| Changes in Inventories | N.A | N.A | N.A |
| Cash Change | -7.48M | -8.88M | -8.33M |
| Cash Flow | -7.61M | -8.87M | -8.32M |
| Capital Expenditures | -1K | -5K | -9K |
| Investments | N.A | N.A | N.A |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | -1K | -5K | -9K |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | N.A | N.A | N.A |
| Other Financing Cash Flows | N.A | N.A | N.A |
| Cash Flow Financing | 143K | N.A | N.A |
| Exchange Rate Effect | -10K | 3K | 1K |
Sierra Oncology Inc dividends (USD)
Total Valuation
Sierra Oncology Inc has a market cap or net worth of $1.34 billion. The enterprise value is $0.
Market Cap
1.34B
Enterprise Value
0
Important Dates
Earnings Date
n.a
Ex-Dividend Date
n.a
Share Statistics
Sierra Oncology Inc has 24.42 million shares outstanding.
Shares Outstanding
24.42M
Float
n.a
Valuation Ratios
The trailing PE ratio is 0.0000 and the forward PE ratio is 0.0000. Sierra Oncology Inc's PEG ratio is 0.0000.
PE Ratio
n.a
Forward PE
n.a
PS Ratio
n.a
PB Ratio
n.a
PEG Ratio
n.a
Stock Price Statistics
The stock price has increased by 0.0000%. The beta is 0.0000, so Sierra Oncology Inc's price volatility has been lower than the market average.
Beta (1Y)
0.0000
52-Week Price Change
0.0000%
50-Day Moving Average
0.00
200-Day Moving Average
0.00
Average Volume (30 Days)
0
Income Statement
In the last 12 months, Sierra Oncology Inc had revenue of $0 and earned $0 in profits. Earnings per share was $.
Revenue
0
Gross Profit
0
EBITDA
0
Earnings per Share
About
Ticker Symbol
SRRA
Reporting Currency
USD
Key Executives
Glover Nicholas
CEO and President
Jagpal Sukhi
Chief Financial Officer
Hassig Christian
Chief Scientific Officer
Thomson Christina
General Counsel
Turner William D.
Chief Reg & Tech Ops Officer